Preclinical and clinical studies have demonstrated the efficacy of ICB with VEGF blockade in HCC (23, 24), paving the way to the US Food and Drug Administration’s approval of combination regimens with ICB that targets PD-L1 and VEGF signaling to remodel the tumor vasculature and enhance immune infiltration. The gene discussed is VEGFA; the disease is neoplasm.